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Molecular imaging in radiology: the latest fad
or the new frontier?
Molecular imaging is “hot”. The past
5 years have seen a gradual increase in
the number of publications on this
topic in concert with the release of a
number of specialized journals and
the foundation of several “Molecular
Imaging Institutes”. More papers uti-
lizing (repeatedly) the term “Molecu-
lar Imaging” have been published in
the last month than in the entire year
2000. What is all this commotion
about? At a first glance it may seem to
be a hype, with a lot of effort being
put into formulating the right defini-
tion of what “Molecular Imaging”
entails. Several renowned researchers
have launched a definition that en-
compasses the visualization/charac-
terization of biological processes in
living organisms [1, 2]. However, at
the April 2005 summit on molecular
imaging organized by the Radiologi-
cal Society of North America (RSNA)
and the Society of Nuclear Medicine
(SNM), a large panel of physicians
and scientists, representing societies
of biomedical imaging professionals
and nuclear medicine specialists from
around the world, agreed that the
existing definitions do not fully cover
the existing variety of imaging tools
available in humans and in animals. In
order to correct this deficit the group
developed the following definition:
“MI techniques directly or indirectly
monitor and record the spatiotemporal
distribution of molecular or cellular
processes for biochemical, biologic,
diagnostic, or therapeutic applica-
tions” [3, 4].
Next to this linguistic exercise,
molecular imaging seems to be char-
acterizedbyabstractimagesconsisting
of (colorful) dots in space, sometimes
superimposed on the anatomical
shadow of a laboratory animal and
rarely of a human. These images can
be quite impressive and pretty, but of
what interest are they to radiologists?
Are these not the products of the toys
of molecular or cell biologists? From a
traditional point of view, in which
radiologists examine gross anatomical
or functional consequences of disease,
molecular imaging may seem to be of
little concern to radiologists. Howev-
er, when looking beyond the pretty
pictures and sometimes complex vo-
cabulary, it becomes clear that mo-
lecular imaging is a serious matter in
modern medicine and that radiologists
need to get involved in this emerging
field if they want to maintain their
central role in health care. After all,
molecular imaging is expected to be
pivotal to early diagnoses, patient
stratification, and early response
assessment.
Aberrant anatomy and organ dys-
function are late manifestations of
disease resulting from pathological
cellular and molecular processes.
Similarly, normalized morphology
and organ function are late indicators
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restorative cellular and molecular
responses. These latter aspects are
what molecular imaging in modern
medicine is all about. Molecular im-
aging is aimed at the characterization,
visualization, and quantification of the
specific cellular and molecular pro-
cesses underlying disease. Central to
this is the use of injectable probes that
specifically target the disease of inter-
est and through which the complex
cellular and molecular behavior of
disease in space and time can be non-
invasively monitored and recorded.
The concept of molecular imaging
is not new. Molecules and molecular
processes have been made visible by
nuclear medicine for decades. Initially,
this was limited to the use of radio-
labeled, native antibodies for the
detection of residual or relapsing
tumor.Morerecently,specificpeptides
binding to specific tumor markers (i.e.
somatostatin-2 receptor) and markers
of increased metabolic (
18F-FDG) ac-
tivity are being employed. While mo-
lecular imaging used to be primarily
linked to imaging modalities not
commonly associated with radiology
departments – i.e., optical imaging
(mostly preclinical research), positron
emission tomography (PET) and sin-
gle photon emission computed to-
mography (SPECT) – modalities such
as computerized tomography (CT),
magnetic resonance imaging (MRI),
and ultrasound are becoming essential
tools in the field, either as a single
modality or in hybrid imaging ap-
proaches, such as in PET-CT, SPECT-
CT, or PET-MR scanners. These
modalitiesofferadvantagesinterms of
increasedanatomical resolutionandan
integrated assessment of anatomy and
physiology with molecular processes.
The convergence of technological
revolutions of recent years within
different fields of research has broad-
ened the horizon for molecular
imaging applications both in basic
research and in clinical settings. These
revolutions involve: the mapping of
the entire human genome; tools to
genetically manipulate cells or organ-
isms; new treatment strategies, in-
cluding molecular and cell-based
therapies, nanotechnology, and state-
of-the-art imaging modalities with
increased spatial and temporal resolu-
tions. Through this convergence, the
potential for “personalized medicine”
is increasing. In the setting of person-
alized medicine, the exact molecular
background of disease in a single
patient could be assessed, upon which
an individualized treatment regimen
could be designed with maximized
therapeutic effect and minimized
adverse effects.
While many issues still need to be
resolved before “personalized medi-
cine” becomes a fact, molecular imag-
ing has already entered the clinical
arena and will only gain in importance
in the coming years [5]. Currently, the
most prominent or pressing clinical
applications of molecular imaging are
in the fields of oncology and cardio-
vascular disease [6–8]. In oncology,
molecular imaging has already resulted
in some breakthroughs in cancer
staging [9, 10] and treatment response
assessment [11, 12], and it is antici-
pated to facilitate early disease
detection. In cardiovascular disease,
molecular imaging is expected to serve
a central role in addressing basic
questions regarding cell therapy for
cardiac repair and vulnerable plaque
detection [13, 14]. In these fields,
tremendous effort is being put into the
development of new probes for clinical
use [5].
Further evidence of molecular
imaging being serious business in
healthcare is provided by the endeav-
ors of the large medical technology
companies. Companies such as GE
Healthcare, Hitachi Medical Corpora-
tion, Philips Medical Systems, Sie-
mens Medical Solutions, and Toshiba
Medical Systems have all created sep-
arate business lines and/or cooperative
agreements with academic or research
institutes to develop and implement
molecular imaging probes, equipment,
and concepts. Moreover, the recent
mergers of General Electric with
Amersham Biosciences (now GE
Healthcare) and of Siemens with Bayer
Diagnostics are clear signs that these
big companies are preparing for the
revolution in diagnostic imaging.
Clearly, molecular imaging is the
new frontier in diagnostic imaging and,
therefore, European radiologists have
to be part in this development. It is the
role of academic and research institu-
tions to gather knowledge and dedicate
resources in this field. The radiological
community needs to invest in this
future by education and participation
in the molecular sciences and by
creating relevantresearchfacilities.But
it is not only research – clinical
radiologists have to be aware of the
ongoing innovations in our profession
and support training and education of
the next generation.
The European Congress of Radiol-
ogy (ECR) and European Society for
Magnetic Resonance in Medicine and
Biology (ESMRMB) are increasingly
trying to bring molecular imaging and
its anticipated importance in future
diagnostic imaging to radiologists’ at-
tentionbyofferingintroductorycourses
and focused sessions on molecular
imaging in their yearly meetings. This
trend must be continued and expanded.
In Europe, two platforms have recently
been created that allow or facilitate
radiologists to join forces amongst
themselves and with other disciplines.
In January 2006, the European Institute
for Biomedical Imaging Research
(EIBIR) was officially instated. The
EIBIR (http://www.eibir.org)i sa ni n -
itiative of the European Society of
Radiology(ESR)havingthepurpose to
promote and facilitate interaction
among researchers involved in the field
of biomedical imaging in Europe,
including molecular imaging. In May
2006 the kick-off meeting of the
European Society for Molecular Imag-
ingwasheldinParis.TheESMI(http://
www.e-smi.eu) is dedicated to the
development and practical application
of molecular imaging withinEurope by
fostering co-operation be-
tween researchers/specialists from
European countries in the various
disciplines in its field. The broad
participation of radiologists in both
these efforts of the scientific commu-
nity in Europe should be encouraged.
2384References
1. Weissleder R, Mahmood U (2001)
Molecular imaging. Radiology
219:316–333
2. Massoud TF, Gambhir SS (2003)
Molecular imaging in living subjects:
seeing fundamental biological pro-
cesses in a new light. Genes Dev
17:545–580
3. Thakur ML, Lentle BC (2005) SNM;
Radiological Society of North America
(RSNA). Joint SNM/RSNA Molecular
Imaging Summit Statement. J Nucl
Med 46:11N–13N 42N
4. Thakur M, Lentle BC (2006) Report of
a summit on molecular imaging. AJR
Am J Roentgenol 186:297–299
5. Jaffer FA, Weissleder R (2005) Molec-
ular imaging in the clinical arena.
JAMA 293:855–862
6. Gambhir SS (2002) Molecular imaging
of cancer with positron emission
tomography. Nat-Rev Cancer 2:683–
693
7. Weissleder R (2006) Molecular imag-
ing in cancer. Science 312:1168–1171
8. Bengel FM, Schachinger V, Dimmeler
S (2005) Cell-based therapies and im-
aging in cardiology. Eur J Nucl Med
Mol Imaging 32:S404–S416
9. Harisinghani MG, Barentsz J, Hahn PF,
Deserno WM, Tabatabaei S, van de
Kaa CH, de la Rosette J, Weissleder R
(2003) Noninvasive detection of clini-
cally occult lymph-node metastases in
prostate cancer. N Engl J Med
348:2491–2499
10. Lardinois D, Weder W, Hany TF,
Kamel EM, Korom S, Seifert B,
von Schulthess GK, Steinert HC (2003)
Staging of non-small-cell lung cancer
with integrated positron-emission
tomography and computed tomogra-
phy. N Engl J Med 348:2500–2507
11. Van den Abbeele AD, Badawi RD
(2002) Use of positron emission to-
mography in oncology and its potential
role to assess response to imatinib
mesylate therapy in gastrointestinal
stromal tumors (GISTs). Eur J Cancer
38:S60–S65
12. Smith-Jones PM, Solit DB, Akhurst T,
Afroze F, Rosen N, Larson SM (2004)
Imaging the pharmacodynamics of
HER2 degradation in response to
Hsp90 inhibitors. Nat Biotechnol
22:701–706
13. Orlic D (2005) BM stem cells and
cardiac repair: where do we stand in
2004? Cytotherapy 7:3–15
14. Fayad ZA (2003) MR imaging for the
noninvasive assessment of athero-
thrombotic plaques. Magn Reson Im-
aging Clin N Am 11:101–113
2385